United States  

CytoDyn files second clinical trial protocol to treat severely ill coronavirus patients with lernlimab

Proactive Investors Wednesday, 1 April 2020
CytoDyn Inc (OTCQB:CYDY) said it has filed a second clinical trial protocol with the US Food and Drug Administration (FDA), this time to treat severely ill coronavirus (COVID-19) patients with its drug leronlimab.  The trial will be conducted under the same FDA-approved Investigational New Drug application that the company used to recently launch a Phase 2 trial of patients with mild-to-moderate symptoms.  The plan is to enroll patients in both protocols as quickly as possible. Severely ill patients will receive leronlimab for two weeks, with the primary endpoint of the study being the 14-day mortality rate. READ: CytoDyn’s Phase 2 trial to treat mild-to-moderately ill coronavirus patients with leronlimab cleared by the FDA Once a coronavirus patient needs a ventilator, the mortality rate becomes very high, CEO Nader Pourhassan noted in a statement. Leronlimab is designed to help by treating the respiratory symptoms caused by the virus. “Once again, the FDA continues to be very supportive of everyone’s efforts to increase access to leronlimab in order to assess its therapeutic benefits for a broader range of COVID-19 patients,” Pourhassan said. "With a study in China indicating the mortality rate among COVID-19 patients requiring mechanical ventilators at more than 85%, the world desperately needs a therapy that can help this patient population.” The company has already administered leronlimab to 10 severely ill patients at a medical facility in New York, separate from the coming trial. An evaluation from diagnostics company IncellDx of the first four of those patients noted “immunological benefits within three days” following treatment with leronlimab, and “lower level of cytokine storm, especially IL-6 and TNF-α, which were reduced significantly.” A cytokine storm occurs when the body overproduces immune cells and their activating compounds, known as cytokines. The overproduction can cause inflammation in the lungs and fluid build-up, which can lead to respiratory issues and be contaminated by a secondary bacterial pneumonia, according to The Scripps Research Institute. In addition to its use as a potential coronavirus treatment, leronlimab has other therapeutic indications as a treatment for HIV and certain breast cancers. Contact Andrew Kessel at [email protected]  Follow him on Twitter @andrew_kessel
0
shares
ShareTweetSavePostSend
 
Video Credit: PA - Press Association STUDIO - Published
News video: Sturgeon: Intensive care influx expected as coronavirus deaths in Scotland rise to 76

Sturgeon: Intensive care influx expected as coronavirus deaths in Scotland rise to 76 01:46

The number of seriously ill coronavirus patients being admitted to intensive care will continue to rise for at least the next two to three weeks, Scotland’s First Minister warned, as she announced that 76 people have now died with the disease. Nicola Sturgeon said there are 147 patients with...

You Might Like


Related videos from verified sources

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19 [Video]

Researchers ID Even More Symptoms Linked To Novel Coronavirus COVID-19

The US Centers for Disease Control and Prevention added six new symptoms to its list for the novel coronavirus COVID-19 last week. They include chills, repeated shaking with chills, muscle pain,..

Credit: Wochit     Duration: 00:40Published
Calls to one St. Louis women’s shelter increase 44 percent [Video]

Calls to one St. Louis women’s shelter increase 44 percent

There is a lot of talk about being safe at home right now, but one St. Louis women’s shelter wants everyone to understand not everyone can be safe at home.

Credit: KTVI     Duration: 02:17Published
With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors [Video]

With graduations being canceled or postponed, Missouri parents drop-off gifts to over 300 seniors

Graduating high school is a moment every senior works towards. But due to the COVID-19 pandemic many may not have the chance to walk across the stage.

Credit: KTVI     Duration: 02:00Published

Related news from verified sources

CytoDyn says coronavirus patients treated with leronlimab show initial improvements after three days

CytoDyn Inc (OTCQB:CYDY) announced Thursday that eight severe coronavirus (COVID-19) patients being treated with its drug leronlimab have shown a significant...
Proactive Investors

CytoDyn announces first site in the southeastern USA to enroll patients in Phase 2 coronavirus trial

CytoDyn Inc (OTCQB:CYDY), the late stage biotech, said partner Novant Health has started enrolling patients in the company's Phase 2 randomized clinical trial...
Proactive Investors

CytoDyn enrolls two patients in Phase 2 coronavirus of leronlimab; 15 severely ill patients treated separately so far

CytoDyn Inc (OTCQB:CYDY) announced Monday that the company has enrolled and begun treating the first two patients in its Phase 2 trial of leronlimab for people...
Proactive Investors


Tweets about this